Authors : Z.Atwani; A.Hinda; A .Amri; Y.Sebbahi; S.Derraji

Volume/Issue : Volume 10 - 2025, Issue 3 - March

Google Scholar : https://tinyurl.com/2w6j7xy7

Scribd : https://tinyurl.com/3wky9k7c

DOI : https://doi.org/10.38124/ijisrt/25mar559

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : Introduction Proton pump inhibitors (PPIs) are key medications in the treatment of acid-related gastric disorders. Their use has become widespread since their introduction to the market. However, this popularity has revealed significant issues of misuse, particularly concerning in the context of self-medication.  Objective This study aims to evaluate self-medication practices related to this class of drugs among the population of the Casablanca-Settat region. The goal is to understand the habits associated with PPI use, identify potential dangers, and propose measures to improve the safety and efficacy of their use.  Material and Methods A cross-sectional, observational, and descriptive study was conducted over two months, from July 17 to September 17, 2023. Data were collected through a comprehensive questionnaire on Google Forms, accessible via a link distributed to patients in the region.  Results The survey included 105 participants, the majority of whom were women. Individuals aged 25 to 65 constituted 59% of the sample, and 81% of the participants had medical coverage. The main reported indications for PPI use were gastroesophageal reflux disease (37.5%), use in combination with non-steroidal anti-inflammatory drugs (19.5%), and dyspepsia (12.5%). A large majority of 79% of the participants expressed satisfaction with their self-medication practice, highlighting the perceived effectiveness of PPIs in managing their symptoms.  Conclusion Although the high satisfaction rate, our study revealed various forms of misuse related to this practice. This concerning reality calls for close collaboration between healthcare professionals, patients, and health institutions to address this issue and promote rational use of this class of drugs. Increased awareness and education about the appropriate use of PPIs can help mitigate the risks associated with self-medication and improve patient outcomes.

Keywords : Proton Pump Inhibitors – Self-Medication – Survey – Patients – Peptic Ulcer.

References :

1. Edinoff AN, Wu NW, Parker K, Dudossat E, Linquest L, Flanagan CJ, et al. Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review. Adv Ther. 1 juin 2023;40(6):2693‑709.
2. Fennerty MB. Acid peptic disease. Postgraduate Medicine [Internet]. 1 sept 2001 [cité 29 mai 2024]; Disponible sur: https://www.tandfonline.com/doi/abs/10.3810/pgm.2001.09.1016
3. Gonzaga CE, Kotze PG, Olandoski M. PREVALENCE OF SELF-MEDICATION FOR DYSPEPTIC SYMPTOMS IN PRIMARY CARE: A BRAZILIAN SURVEY. Arq Gastroenterol. 22 oct 2021;58:364‑9.
4. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277‑305.
5. Rathod P, Sharma S, Ukey U, Sonpimpale B, Ughade S, Narlawar U, et al. Prevalence, Pattern, and Reasons for Self-Medication: A Community-Based Cross-Sectional Study From Central India. Cureus. 15(1):e33917.
6. CP-2013-09-18-3eme-forum-de-automedication.pdf [Internet]. [cité 21 févr 2024]. Disponible sur: https://neres.fr/wp-content/uploads/2019/01/CP-2013-09-18-3eme-forum-de-automedication.pdf
7. World Health Organization. Guidelines for the regulatory assessment of medicinal products for use in self-medication. 2000.
8. CP-2015-06-23-3eme-observatoire-europeen-sur-automedication.pdf [Internet]. [cité 21 févr 2024]. Disponible sur: https://neres.fr/wp-content/uploads/2019/01/CP-2015-06-23-3eme-observatoire-europeen-sur-automedication.pdf
9. Prilosec OTC Product Monograph [Internet]. [cité 20 sept 2023]. Disponible sur: https://prilosecotc.com/en-us/articles/prilosec-otc/product-monograph
10. Les femmes sont plus susceptibles de recourir à l’automédication que les hommes [Internet]. CORDIS | European Commission. [cité 21 avr 2024]. Disponible sur: https://cordis.europa.eu/article/id/33315-spanish-research-shows-women-are-more-likely-to-selfmedicate-than-men/fr
11. Chattha IR, Zaffar S, Tariq S, Siddiqui W, Zaman K, Kamran R, et al. Prevalence of Self-medication for Acid Peptic Disease amongst People of Manawa, Lahore. Cureus [Internet]. 30 janv 2020 [cité 5 oct 2023]; Disponible sur: https://www.cureus.com/articles/27397-prevalence-of-self-medication-for-acid-peptic-disease-amongst-people-of-manawa-lahore
12. Borum ML. GASTROINTESTINAL DISEASES IN WOMEN. Medical Clinics of North America. 1 janv 1998;82(1):21‑50.
13. Common Gastrointestinal (GI) Problems in Women | ACG [Internet]. American College of Gastroenterology. [cité 21 avr 2024]. Disponible sur: https://gi.org/topics/common-gi-problems-in-women/
14. Isacson D, Bingefors K. Epidemiology of analgesic use: a gender perspective. European Journal of Anaesthesiology | EJA. 2002;19:5.
15. Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. sept 1997;2(9):839‑45.
16. Kayalvizhi S, Senapathi DR. EVALUATION OF THE PERCEPTION, ATTITUDE AND PRACTICE OF SELF MEDICATION AMONG BUSINESS STUDENTS IN 3 SELECT CITIES, SOUTH INDIA. 1(3).
17. Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, et al. Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition. Gut Liver. 15 nov 2020;14(6):707‑26.
18. Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974–2002. BMC Gastroenterol. 20 avr 2009;9(1):25.
19. Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M, et al. Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants. Official journal of the American College of Gastroenterology | ACG. mars 2007;102(3):507.
20. fiche_bum_-_bon_usage_des_inhibiteurs_de_la_pompe_a_protons_ipp.pdf [Internet]. [cité 19 nov 2023]. Disponible sur: https://www.has-sante.fr/upload/docs/application/pdf/2022-09/fiche_bum_-_bon_usage_des_inhibiteurs_de_la_pompe_a_protons_ipp.pdf
21. COMMISSION DE LA TRANSPARENCE - HAS. Médicaments inhibiteurs de la pompe à protons chez l’adulte : réévaluation. 2009.
22. afssaps. RECOMMANDATIONS DE BONNE PRATIQUE : LES ANTISECRETOIRES GASTRIQUES  CHEZ L’ADULTE. 2007.
23. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Official journal of the American College of Gastroenterology | ACG. juill 2017;112(7):988.
24. argumentaire_-_depistage_de_linfection_a_helicobacter_pylori.pdf [Internet]. [cité 18 mai 2024]. Disponible sur: https://www.has-sante.fr/upload/docs/application/pdf/2010-08/argumentaire_-_depistage_de_linfection_a_helicobacter_pylori.pdf
25. Khan Z, Alastal Y, Khan MA, Khan MS, Khalil B, Shrestha S, et al. On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice. 12 août 2018;2018:e6417526.
26. Is It Time for Noncontinuous Therapy for Gastroesophageal Reflux Disease? – Gastroenterology & Hepatology [Internet]. [cité 26 mai 2024]. Disponible sur: https://www.gastroenterologyandhepatology.net/archives/may-2024/is-it-time-for-noncontinuous-therapy-for-gastroesophageal-reflux-disease/
27. Research C for DE and. Prilosec OTC (omeprazole) Information. FDA [Internet]. 11 mars 2018 [cité 21 mars 2024]; Disponible sur: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/prilosec-otc-omeprazole-information
28. Research C for DE and. Over-The-Counter (OTC) Heartburn Treatment. FDA [Internet]. 17 nov 2023 [cité 21 mars 2024]; Disponible sur: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/over-counter-otc-heartburn-treatment
29. Research C for DE and. Questions and Answers on Zegerid OTC. FDA [Internet]. 11 mars 2018 [cité 21 mars 2024]; Disponible sur: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/questions-and-answers-zegerid-otc
30. Wong N, Reddy A, Patel A. Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders. Gastroenterol Hepatol (N Y). déc 2022;18(12):693‑700.
31. Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther. 13 déc 2018;9(7):63‑8.
32. Kim DK, Lee KH, Kim SJ, Kim SJ, Lee SJ, Park CH, et al. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. J Pharmacol Exp Ther. juin 2019;369(3):318‑27.
33. Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776.
34. Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 30 juill 2018;24(3):334‑44.
35. ANSM. THESAURUS DES INTERACTIONS MÉDICAMENTEUSES. 2023.
36. Résumé des caractéristiques du produit - LANSOPRAZOLE ALMUS PHARMA 15 mg, gélule gastro-résistante - Base de données publique des médicaments [Internet]. [cité 18 déc 2023]. Disponible sur: https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=69966450&typedoc=R
37. Crauwels H, van Heeswijk RPG, Stevens M, Buelens A, Vanveggel S, Boven K, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15(2):87‑101.
38. Résumé des Caractéristiques du Produit [Internet]. [cité 18 déc 2023]. Disponible sur: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0231883.htm
39. Résumé des Caractéristiques du Produit [Internet]. [cité 22 mai 2024]. Disponible sur: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0236522.htm
40. Résumé des Caractéristiques du Produit [Internet]. [cité 18 déc 2023]. Disponible sur: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0307017.htm
41. Résumé des caractéristiques du produit - PARIET 20 mg, comprimé gastro-résistant - Base de données publique des médicaments [Internet]. [cité 18 déc 2023]. Disponible sur: https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=62909137&typedoc=R
42. Résumé des caractéristiques du produit - PANTOPRAZOLE CRISTERS PHARMA 40 mg, comprimé gastro-résistant - Base de données publique des médicaments [Internet]. [cité 18 déc 2023]. Disponible sur: https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=62034970&typedoc=R
43. Lee TH, Chan A, Bryan W, Park L, Hashem M, Townsend M, et al. Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. J Viral Hepat. avr 2021;28(4):630‑6.
44. Stark JE, Montgomery CM. Administering a Soda Beverage With the Hepatitis C Treatment Sofosbuvir/Velpatasvir and the Proton-Pump Inhibitor Pantoprazole: A Case Report. Journal of Pharmacy Practice. 30 juin 2023;08971900231183036.
45. Wedemeyer RS, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf. 2014;37(4):201‑11.
46. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors - where do we stand in 2012? World J Gastroenterol. 14 mai 2012;18(18):2161‑71.
47. Pang J, Wu Q, Zhang Z, Zheng T zhang, Xiang Q, Zhang P, et al. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis. IJC Heart & Vasculature. 1 juin 2019;23:100317.
48. Rochoy M, Dubois S, Glantenet R, Gautier S, Lambert M. [Gastric acid rebound after a proton pump inhibitor: Narrative review of literature]. Therapie. 2018;73(3):237‑46.
49. Benedeto Stojanov D, Koraćević G, Stojanov D, Koraćević M, Ignjatović N. REBOUND PHENOMENON OF PROTON PUMP INHIBITOR THERAPY. AMM. 15 juin 2021;60(02):64‑8.
50. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. juill 2009;137(1):80‑7, 87.e1.
51. Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased Proximal Reflux in a Hypersensitive Esophagus Might Explain Symptoms Resistant to Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology. 1 oct 2014;12(10):1647‑55.
52. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy: clinical implications. Am J Pharmacogenomics. 2003;3(5):303‑15.
53. Deshpande N, V. S, V. V. RK, H. V. V. M, M. S, Banerjee R, et al. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene. 18 juin 2016;9:159‑64.
54. Rani S, Padh H. Inter-individual variation in pharmacokinetics of proton pump inhibitors in healthy Indian males. Indian Journal of Pharmaceutical Sciences. 2006;68(6):754.
55. Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. Int J Clin Phar,. oct 2015;37(5):709‑16.
56. Boardman HF, Delaney BC, Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Current Medical Research and Opinion. 3 juill 2015;31(7):1309‑18.
57. Keber E, Rocco P, Musazzi UM, Morselli-Labate AM, Floris NP, Pedrazzini A, et al. The management of upper gastrointestinal symptoms: A study on community pharmacies in Italy. Pharmacia. 7 mai 2021;68(2):401‑9.
58. Menees SB, Guentner A, Chey SW, Saad R, Chey WD. How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation? Official journal of the American College of Gastroenterology | ACG. nov 2015;110(11):1516.
59. Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol. janv 2004;2(1):17‑21.
60. Inadomi JM, Fendrick AM. PPI use in the OTC era: Who to treat, with what, and for how long? Clin Gastroenterol Hepatol. mars 2005;3(3):208‑15.
61. Haag S, Andrews JM, Katelaris PH, Gapasin J, Galmiche JP, Hunt R, et al. Management of Reflux Symptoms with Over-the-Counter Proton Pump Inhibitors: Issues and Proposed Guidelines. Digestion. 2009;80(4):226‑34.
62. Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, et al. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017;77(5):547‑61.
63. Clere N. Stress et troubles digestifs. Actualités Pharmaceutiques. 1 nov 2018;57(580):43‑6.
64. Melis G, Gelormino E, Marra G, Ferracin E, Costa G. The Effects of the Urban Built Environment on Mental Health: A Cohort Study in a Large Northern Italian City. Int J Environ Res Public Health. nov 2015;12(11):14898‑915.
65. Lederbogen F, Kirsch P, Haddad L, Streit F, Tost H, Schuch P, et al. City living and urban upbringing affect neural social stress processing in humans. Nature. juin 2011;474(7352):498‑501.
66. Le cortex cingulaire antérieur : contrôle exécutif, contrôle émotionnel [Internet]. 2021 [cité 19 juin 2024]. Disponible sur: https://neuronup.fr/neuropsychologie-et-informations/cerveau/le-cortex-cingulaire-anterieur-controle-executif-controle-emotionnel/
67. Tutuian R, Clinical Lead Outpatient Services and Gastrointestinal Function Laboratory. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol. avr 2010;24(2):91‑7.
68. Mungan Z, Pınarbaşı Şimşek B. Which drugs are risk factors for the development of gastroesophageal reflux disease? Turk J Gastroenterol. déc 2017;28(Suppl 1):S38‑43.
69. Zheng Z, Margolis KL, Liu S, Tinker LF, Ye W. Effects of Estrogen With and Without Progestin and Obesity on Symptomatic Gastroesophageal Reflux. Gastroenterology. juill 2008;135(1):72.